

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2819428

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
FRANCIS J. CARR	03/12/2014
TIMOTHY D. JONES	03/12/2014
SIMON WILLIAM KEEN	03/12/2014
RECEIVING PARTY DATA	
Name:	VASCULAR PHARMACEUTICALS, INC.
Street Address:	830 MARY ELLEN JONES BUILDING
Internal Address:	116 MANNING DRIVE
City:	CHAPEL HILL
State/Country:	NORTH CAROLINA
Postal Code:	27599
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14015457
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	gbailey@myersbigel.com
Correspondent Name:	GWEN R. BAILEY/MBSS
Address Line 1:	4140 PARKLAKE AVENUE, SUITE 600
Address Line 4:	RALEIGH, NORTH CAROLINA 27612
ATTORNEY DOCKET NUMBER:	5470-628TS
NAME OF SUBMITTER:	GWEN R. BAILEY
SIGNATURE:	/grb/
DATE SIGNED:	04/17/2014
Total Attachments: 3	
source=5470-628TS_Assignment2#page1.tif	
source=5470-628TS_Assignment2#page2.tif	
source=5470-628TS_Assignment2#page3.tif	

ASSIGNMENT

THIS ASSIGNMENT, made by us, **Francis J. Carr**, a citizen of the United Kingdom, having an address at The Holdings, Balmedie, Aberdeen AB23 8WU, United Kingdom; **Timothy D. Jones**, a citizen of the United Kingdom, having an address at 27 Brick Row, Babraham, Cambridgeshire CB22 3AJ, United Kingdom; and **Simon William Keen**, a citizen of the United Kingdom, having an address at 59 High Street, West Wickham, Cambridgeshire CB21 4SB, United Kingdom;

WITNESSETH: That,

WHEREAS, we are employees of Antitope Limited, and we are joint inventors, along with David Clemmons, Laura Maile, and Michael Naso, of certain new and useful improvements in **MONOCLONAL ANTIBODIES FOR ENHANCING OR INHIBITING INSULIN-LIKE GROWTH FACTOR-I (IGF-I)**, for which U.S. Provisional Patent Application No. 61/695,409 was filed on August 31, 2012; PCT International Application Serial No. PCT/US2013/057484 was filed on August 30, 2013; and U.S. Patent Application No. 14/015,457 was filed on August 30, 2013 in the United States Patent and Trademark Office and;

WHEREAS, **Vascular Pharmaceuticals, Inc.**, a Delaware corporation, having a principal place of business at 830 Mary Ellen Jones Building, 116 Manning Drive, Chapel Hill, NC 27599, hereinafter referred to as assignee, is desirous of acquiring our partial right, title and interest in and to the invention as described in said applications, and in and to any and all Letters Patent which shall be granted therefor in the United States of America and all foreign countries, pursuant to the Research Agreement between Vascular Pharmaceuticals, Inc. and Antitope Limited, having an effective date of May 11, 2009 and the Antitope Limited & Vascular Pharmaceuticals, Inc. License Agreement having an effective date of May 11, 2009;

NOW, THEREFORE, To Whom It May Concern, be it known that for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, we have sold and by these presents do hereby sell, assign, transfer, and convey unto the said assignee, its successors and assigns, our partial right, title, and interest in and to said invention and applications, and in and to any and all subsequent patent applications which claim the benefit of priority from said applications including regular utility, continuations, and continuations-in-part, or divisions thereof, and in and to any and all Letters Patent of the United States of America and all foreign

countries or reissues or other forms of protection thereof which may be granted for the invention in or on applications claiming the benefit of priority from said applications, for the full end of the term for which said Letters Patent may be granted along with any term extensions thereof or therefor, together with the right to claim the benefit of priority from said applications in all foreign countries in accordance with the International Convention, the same to be held and enjoyed by said assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by us if this assignment and sale had not been made.

We further covenant and agree that, at the time of the execution and delivery of these presents, as joint inventors, we possess a partial right, title and interest to the invention and applications above-mentioned, and that we have the unencumbered right and authority to make this assignment of our partial right, title and interest, pursuant to the Research Agreement between Vascular Pharmaceuticals, Inc. and Antitope Limited, having an effective date of May 11, 2009 and the Antitope Limited & Vascular Pharmaceuticals, Inc. License Agreement having an effective date of May 11, 2009.

We further covenant and agree to promptly communicate to said assignee or its representatives any facts known to us relating to said invention, to testify in any interference or legal proceedings involving said invention, to execute any additional papers which may be requested to confirm the right of the assignee, its representatives, successors, or assigns to secure patent or similar protection for the said invention in all countries and to vest in the assignee complete title to the said invention and Letters Patent, without further compensation, but at the expense of said assignee, its successors, assigns, and other legal representatives; and we hereby instruct, and further covenant and agree to bind our heirs, legal representatives, and assigns, to do same, without further compensation, but at the expense of said assignee or its representatives.

IN WITNESS WHEREOF, I have hereunto set my hand and seal on this 12th day of
March, 2014.




FRANCIS J. CARR

(SEAL)



Witness




Witness

IN WITNESS WHEREOF, I have hereunto set my hand and seal on this 12th day of
March, 2014.




TIMOTHY D. JONES

(SEAL)



Witness




Witness

IN WITNESS WHEREOF, I have hereunto set my hand and seal on this 12th day of
March, 2014.




SIMON WILLIAM KEEN

(SEAL)



Witness ALICE IND



Witness EMMA JENKINS